ALX Oncology/$ALXO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ALX Oncology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Ticker
$ALXO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
65
ISIN
US00166B1052
Website
ALX Oncology Metrics
BasicAdvanced
$24M
-
-$2.45
1.21
-
Price and volume
Market cap
$24M
Beta
1.21
52-week high
$8.78
52-week low
$0.41
Average daily volume
390K
Financial strength
Current ratio
5.471
Quick ratio
5.268
Long term debt to equity
14.595
Total debt to equity
18.784
Interest coverage (TTM)
-79.93%
Profitability
EBITDA (TTM)
-135.656
Management effectiveness
Return on assets (TTM)
-51.16%
Return on equity (TTM)
-102.99%
Valuation
Price to book
0.27
Price to tangible book (TTM)
0.27
Price to free cash flow (TTM)
-0.22
Free cash flow yield (TTM)
-454.59%
Free cash flow per share (TTM)
-205.74%
Growth
Earnings per share change (TTM)
-33.11%
3-year earnings per share growth (CAGR)
1.90%
What the Analysts think about ALX Oncology
Analyst ratings (Buy, Hold, Sell) for ALX Oncology stock.
ALX Oncology Financial Performance
Revenues and expenses
ALX Oncology Earnings Performance
Company profitability
ALX Oncology News
AllArticlesVideos
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
GlobeNewsWire·4 weeks ago
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
GlobeNewsWire·1 month ago
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ALX Oncology stock?
ALX Oncology (ALXO) has a market cap of $24M as of June 28, 2025.
What is the P/E ratio for ALX Oncology stock?
The price to earnings (P/E) ratio for ALX Oncology (ALXO) stock is 0 as of June 28, 2025.
Does ALX Oncology stock pay dividends?
No, ALX Oncology (ALXO) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next ALX Oncology dividend payment date?
ALX Oncology (ALXO) stock does not pay dividends to its shareholders.
What is the beta indicator for ALX Oncology?
ALX Oncology (ALXO) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.